Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines

(2021) Joseph A. Lewnard et al.   EPIDEMIOLOGY

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates

(2021) Leora R Feldstein et al.   JOURNAL OF INFECTIOUS DISEASES

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021

(2021) Tamara Pilishvili et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

(2021) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

(2021) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic

(2021) Gregory A. Roth et al.   JAMA Network Open

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

(2021) Jake A Ruddy et al.   ANNALS OF THE RHEUMATIC DISEASES

Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019–2020: A Test-Negative Study

(2021) Carlos G Grijalva et al.   CLINICAL INFECTIOUS DISEASES

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

(2020) Stephen A. Lauer et al.   ANNALS OF INTERNAL MEDICINE

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020

(2020) Shikha Garg et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

(2020) Andrew Rambaut et al.   Nature Microbiology

Incorporating real-time influenza detection into the test-negative design for estimating influenza vaccine effectiveness: The real-time test-negative design (rtTND)

(2020) Leora R Feldstein et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevention of influenza hospitalization among adults in the US, 2015–16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)

(2018) J M Ferdinands et al.   JOURNAL OF INFECTIOUS DISEASES

Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season

(2017) Michael L. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Raising Type 1 Error Rate Improve Power to Detect Interactions in Linear Regression Models? A Simulation Study

(2013) Casey P. Durand   PLoS One

The case test-negative design for studies of the effectiveness of influenza vaccine

(2013) Ivo M. Foppa et al.   VACCINE